A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis Konstantinos A. Papas, Marci K. Sontag,

Slides:

Advertisements

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Advertisements

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Scott D. Sagel, Marci K. Sontag, Meg M

Samantha A. Woodruff, Marci K. Sontag, Frank J. Accurso, Ronald J

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis Marco Zampoli, Komala Pillay, Henri Carrara,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Raphaël Chiron, Y. Yaël Grumbach, Nga V. T

Cirrhosis and other liver disease in cystic fibrosis

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Rate of improvement of CF life expectancy exceeds that of general population— Observational death registration study Matthew N. Hurley, Tricia M. McKeever,

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

Pulmonary exacerbations in CF patients with early lung disease

Safety and early treatment effects of the CXCR2 antagonist SB in patients with cystic fibrosis Richard B. Moss, Sunil J. Mistry, Michael W. Konstan,

Fiona K. Dunlevy, S. Lorraine Martin, Francine de Courcey, J

Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation Shahid I. Sheikh, Frederick R. Long, Karen.

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial S.K. Kabra, R. Pawaiya, Rakesh Lodha,

Vitamin A and lung function in CF

Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis Donna Drury, Vijay Laxmi Grey, Guylaine Ferland, Caren Gundberg,

Cytokines in nasal lavages and plasma and their correlation with clinical parameters in cystic fibrosis Marthe S. Paats, Ingrid M. Bergen, Marleen Bakker,

A.H. Gifford Journal of Cystic Fibrosis

Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis Elizabeth F. Shead, Charles S. Haworth,

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Tregony Simoneau, Gregory S. Sawicki, Carly E. Milliren, Henry A

M. Al-Aloul, M. Jackson, G. Bell, M. Ledson, M. Walshaw

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India Shivaram S. Shastri, Madhulika Kabra, Sushil.

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Depression and anxiety in adolescents and adults with cystic fibrosis in the UK: A cross- sectional study Alistair J.A. Duff, Janice Abbott, Carolyn Cowperthwaite,

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Stability of interleukin 8 and neutrophil elastase in bronchoalveolar lavage fluid following long-term storage Luke J. Berry, Barbara Sheil, Luke Garratt,

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

Soluble inflammation markers in nasal lavage from CF patients and healthy controls Natalie Beiersdorf, Matthias Schien, Julia Hentschel, Wolfgang Pfister,

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R

Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis Hanne Vebert Olesen, Uffe Holmskov, Peter Oluf Schiøtz, Grith Lykke Sørensen

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients Gregory S. Sawicki, Will Chou, Karina.

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

Beta-lactam allergy in adults with cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa C.E. Wainwright, A.L. Quittner, D.E.

Theresa A. Laguna, Scott D. Sagel, Marci K. Sontag, Frank J. Accurso

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Cystic fibrosis and pregnancy in the modern era: A case control study

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Presentation transcript:

A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis Konstantinos A. Papas, Marci K. Sontag, Churee Pardee, Ronald J. Sokol, Scott D. Sagel, Frank J. Accurso, Jeffrey S. Wagener Journal of Cystic Fibrosis Volume 7, Issue 1, Pages 60-67 (January 2008) DOI: 10.1016/j.jcf.2007.05.001 Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 Box and whisker plots for serum levels of A) β-carotene (μg/ml), B) CoQ10 (μg/ml) and C) γ-Tocopherol (μg/ml) at each of the six study visits. Supplementation with CF-1 commenced after visit 2. Whiskers denote minimum and maximum observations, box signifies 25th percentile, median, and 75th percentile with mean represented by a ⊕. Box width varies with number of observations. Journal of Cystic Fibrosis 2008 7, 60-67DOI: (10.1016/j.jcf.2007.05.001) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 Measures of inflammatory mediators in induced sputum collected at Pre-dosing visit of CF-1 antioxidant solution (visit 2) and Post-Dosing (week 4 or 8). Panel A) Total Neutrophils (103/ml), p=0.04, B) Myeloperoxidase (pg/ml) p=NS and C) IL-8 (pg/ml), p=NS. Journal of Cystic Fibrosis 2008 7, 60-67DOI: (10.1016/j.jcf.2007.05.001) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 3 Inflammatory mediators at baseline are inversely correlated with CoQ10. (μg/ml), Panel A) Total neutrophils (103/ml) R=−0.68, p=0.04; Panel B) MPO (pg/ml) R=−0.73, p=0.02, and Panel C) IL-8 (pg/ml), R=−0.68, p=0.04. Journal of Cystic Fibrosis 2008 7, 60-67DOI: (10.1016/j.jcf.2007.05.001) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions

Fig. 4 Antioxidant score [(postCoQ10–preCoQ10)/preCoQ10+(postβ-carotene–preβ-carotene)/preβ-carotene+(postγ-tocopherol–preγ-tocopherol)/preγ-tocopherol] is inversely correlated with change in inflammatory mediators after treatment with CF-1. Panel A) Total neutrophils (103/ml) R=−0.80, p=0.03; Panel B) IL-8 (pg/ml) R=−0.82, p=0.03 and Panel C) MPO (pg/ml) R=−0.66, p=0.11. Journal of Cystic Fibrosis 2008 7, 60-67DOI: (10.1016/j.jcf.2007.05.001) Copyright © 2007 European Cystic Fibrosis Society Terms and Conditions